IMMUNOLOGICAL, BIOCHEMICAL, AND MOLECULAR STUDIES ON EPITHELIAL OVARIAN CANCER

该项目的主要目标是生成有关生物学的数据， 卵巢上皮癌（EOC），特别强调 鉴定和表征这种特征性抗原 肿瘤类型正在进行的研究已经确定了四个抗原系统 与EOC特别相关的：1）MX35抗原; 2）CA-125抗原; 3） 粘蛋白抗原，例如，MUC-1;和4）血型相关特异性， 比如刘易斯。这个项目将强调详细的生物化学， 免疫化学和这些抗原的分子分析。MX35抗原具有 CA-125被鉴定为95，000道尔顿的糖蛋白，CA-125被鉴定为粘蛋白， 型分子。其中一个目标是克隆编码这种蛋白质的基因 这些分子的一部分，目的是了解它们的分子 化妆品和功能。对于粘蛋白抗原，我们计划在 详细描述了MUC-1粘蛋白和CA-125的糖基化特征 抗原的目的是确定糖基化如何促进糖基化。 针对这些抗原的肿瘤特异性抗体，以及是否 粘蛋白糖基化是组织特异性特征。实验 也可能为EOC的免疫治疗指明新的靶点。最终 我们的目标是确定糖表位的肽模拟物 EOC的特征，例如，Le/y，可以作为疫苗， 抗肿瘤反应的发展。总体而言，该项目旨在 了解卵巢癌的免疫原性， 开发新的治疗方法。

The main goals of this project are to generate data concerning the biology of epithelial ovarian cancer (EOC) with a special emphasis on the identification and characterization of antigens characteristic of this tumor type. On-going studies have identified four antigenic systems particularly pertinent to EOC: 1) MX35 antigen; 2) CA-125 antigen; 3) mucin antigens, e.g., MUC-1; and 4) blood group-related specificities, such as Lewis. This project will emphasize the detailed biochemical , immunochemical, and molecular analysis of these antigens. MX35 antigen has been identified as a glycoprotein of 95,000 dalton and CA-125 as a mucin- type molecule. One goal will be to clone the genes coding for the protein portion of these molecules, with the aim of understanding their molecular makeup and perhaps function. For mucin antigens, we plan to analyze in detail the glycosylation characteristics of MUC-1 mucin and CA-125 antigen. The goal is to determine how glycosylation contributes to the tumor-specific of antibodies directed towards these antigens and whether mucin glycosylation is a tissue-specific characteristic. The experiments could also point towards new targets for the immunotherapy of EOC. A final goal will be to determine whether peptide mimics of carbohydrate epitopes characteristic of EOC, e.g., Le/y, can serve as vaccines for the development of anti-tumor responses. Overall, the project aims at understanding the immunogenicity of ovarian cancer and using this information to develop new therapeutic approaches.